Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ma, Min ^a   Ren, Qian ^a   Yang, Chun ^a   Zhang, Ji Chun ^a   Yao, Wei ^a   Dong, Chao ^a   Ohgi, Yuta ^b   Futamura, Takashi ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANA 12 COMPOUND; ANTIDEPRESSANT AGENT; AZEPINE DERIVATIVE; BENZAMIDE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BREXPIPRAZOLE; FLUOXETINE; QUINOLONE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE;

ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMBINATION DRUG THERAPY; DENDRITIC SPINE; DISEASE MODEL; DRUG EFFECT; MAJOR DEPRESSION; MALE; METABOLISM; MOUSE; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZEPINES; BEHAVIOR, ANIMAL; BENZAMIDES; BRAIN-DERIVED NEUROTROPHIC FACTOR; DENDRITIC SPINES; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FLUOXETINE; MALE; MICE; MICE, INBRED C57BL; PHENOTYPE; QUINOLONES; RECEPTOR, TRKB; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION; THIOPHENES;

EID: 85006699290     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39209     Document Type: Article

References (57)

1. Barbee, J. G., Conrad, E. J. & Jamhour, N. J. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry. 65, 975-981 (2004)
2. Nelson, J. C. & Papakostas, G. I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebocontrolled randomized trials. Am J Psychiatry. 166, 980-991 (2009)
3. Papakostas, G. I. et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 66, 1326-1330 (2005)
4. Papakostas, G. I. et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 68, 826-831 (2007)
5. Shelton, R. C. & Papakostas, G. I. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 117, 253-259 (2008)
6. Brunner, E. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology. 39, 2549-2559 (2014)
7. Papakostas, G. I. et al. Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results From a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 172, 1251-1258 (2015)
8. Abdallah, C. G. et al. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 66, 509-523 (2015)
9. Newport, D. J. et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 172, 950-966 (2015)
10. Kishimoto, T. et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 46, 1459-1472 (2016)
11. Rogoz, Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol Rep. 65, 1536-1544 (2013)
12. Blier, P. Rational site-directed pharmacotherapy for major depressive disorder. Int J Neuropsychopharmacol. 17, 997-1008 (2014)
13. Maeda, K. et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 350, 589-604 (2014)
14. Ishima, T. et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 25, 505-511 (2015)
15. Maeda, K. et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 350, 605-614 (2014)
16. Yoshimi, N. et al. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav. 124, 245-249 (2014)
17. Yoshimi, N., Futamura, T. & Hashimoto, K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 25, 356-364 (2015)
18. Citrome, L. Brexpiprazole: a new dopamine D2receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today (Barc). 51, 397-414 (2015)
19. Citrome, L., Stensbol, T. B. & Maeda, K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 5, 1219-1229 (2015)
20. Correll, C. U. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: A 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 172, 870-880 (2015)
21. Das, S. et al. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 6, 39-54 (2016)
22. Kane, J. M. et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 164, 127-135 (2015)
23. McKeage, K. Adjunctive brexpiprazole: A review in major depressive disorder. CNS Drugs. 30, 91-99 (2016)
24. Stahl, S. M. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr. 21, 1-6 (2016)
25. Thase, M. E. et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebocontrolled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 76, 1224-1231 (2015)
26. Thase, M. E. et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebocontrolled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 76, 1232-1240 (2015)
27. Nestler, E. J. et al. Neurobiology of depression. Neuron. 34, 13-25 (2002)
28. Hashimoto, K., Shimizu, E. & Iyo, M. Critical role of brain-derived neurotrophic factor in mood disorder. Brain Res Brain Res Rev. 45, 104-114 (2004)
29. Duman, R. S. & Monteggia, L. M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 59, 1116-1127 (2006)
30. Hashimoto, K. Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions. Psychiatry Clin Neurosci. 64, 341-357 (2010)
31. Hashimoto, K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression. Prog Neurobiol. 100, 15-29 (2013)
32. Castren, E. Neurotrophins and psychiatric disorders. Handb Exp Pharmacol. 220, 461-479 (2014)
33. Zhang, J. C., Yao, W. & Hashimoto, K. Brain-derived neurotrophic factor (BDNF) - TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol. 14, 721-731 (2016)
34. Ren, Q. et al. BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms. Transl Psychiatry. 5, e666 (2015)
35. Shirayama, Y. et al. Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol. 25, 2449-2458 (2015)
36. Yang, C. et al. Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol. 18, pyu121 (2015)
37. Yang, C. et al. R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 5, e632 (2015)
38. Zhang, J. C. et al. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychophamacol. 18, pyu077 (2015)
39. Zhang, J. C. et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl). 232, 4325-4335 (2015)
40. Cazorla, M. et al. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest. 121, 1846-1857 (2011)
41. Yang, B. et al. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl). 233, 3647-3657 (2016)
42. Bjorkholm, C. et al. Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat. Eur Neuropsychopharmacol. 25, 1842-1847 (2015)
43. Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 475, 91-95 (2011)
44. Lepack, A. E. et al. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 18, pyu033 (2014)
45. Liu, W. X. et al. Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression. Psychopharmacology (Berl). 233, 405-415 (2016)
46. Sun, H. L. et al. Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model. Transl Psychiatry. 6, e741 (2016)
47. Yang, B. et al. Regional differences in the expression of brain-derived neurotrophic factor (BDNF) pro-peptide, proBDNF, and preproBDNF in the brain confer stress resilience. Eur Arch Psychiatry Clin Neurosci., 266, 765-769 (2016) doi: 10.1007/s00406-016-0693-6
48. Jang, S. W. et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 107, 2687-2692 (2010)
49. Shirayama, Y. et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 22, 3251-3261 (2002)
50. Nestler, E. J. & Carlezon, W. A. Jr. The limbic dopamine reward circuit in depression. Biol Psychiatry. 59, 1151-1159 (2006)
51. Duman, R. S. & Aghajanian, G. K. Synaptic dysfunction in depression: Potential therapeutic targets. Science. 338, 68-72 (2012)
52. Ohgi, Y., Futamura, T. & Hashimoto, K. Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med. 15, 206-221 (2015)
53. McEwen, B. S. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 87, 873-904 (2007)
54. Ren, Q. et al. 7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology (Berl). 231, 159-166 (2014)
55. Berton, O. et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 311, 864-868 (2006)
56. Golden, S. A. et al. A standardized protocol for repeated social defeat stress in mice. Nat Protoc. 6, 1183-1191 (2011)
57. Ren, Q. et al. Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci USA 113, E1944-E1952 (2016)